Prospective Evaluation of AI R&D Tool for Patient Stratification: a Trial for Renal Immuno-oncology Model Experimental Evaluation 2
Megadott ok: Lack of funding
Key facts
- Where
- Cambridge és London, Egyesült KirályságSee the 4 sites
Where in Egyesült Királyság
- Addenbrooke's HospitalCambridge, Egyesült KirályságNo longer taking part
- Imperial College Healthcare NHS TrustLondon, Egyesült KirályságNo longer taking part
- Mount Vernon Cancer CentreLondon, Egyesült KirályságNo longer taking part
- Royal Free NHS Foundation TrustLondon, Egyesült KirályságNo longer taking part
Trial details
- Who runs it
- Ourotech, Inc.
- Trial code
- NCT06264479
- Record updated
- 2025. július 30.
- Original description
Pear Bio has developed a predictive biomarker technology that combines 3D cell culture, microscopy and computer vision to measure the response of an individual patient's tumor sample to different systemic therapy regimens that are tested simultaneously ex vivo.Read full original descriptionShow less
Pear Bio has developed a predictive biomarker technology that combines 3D cell culture, microscopy and computer vision to measure the response of an individual patient's tumor sample to different systemic therapy regimens that are tested simultaneously ex vivo.
This study will recruit patients with advanced or metastatic kidney cancer who are due to start a clinically-indicated new line of therapy.
The oncologist will be blinded to the response on the Pear Bio test (the test will be run in parallel with the patient's treatment). The primary objective of this study is to establish the sensitivity and specificity of Pear Bio's test results against patient outcomes (objective response, progression-free survival, depth and duration of response, overall survival).
Inclusion:; Able to give written informed consent prior to admission to this study; Female or male aged ≥18 years; Evidence of advanced RCC with intention to receive systemic therapy, defined as:; Clinical suspicion of advanced RCC with intention to undergo a clinically-mandated biopsy and subsequent systemic therapy OR; Histological evidence of advanced RCC with intention to undergo subsequent systemic therapy and willing to undergo additional research biopsy; At least one lesion evaluable under RECIST 1.1 criteria; Willing to donate at least two additional core biopsy samples prior to starting subsequent systemic therapy; Willing to undergo venous sampling for 40mL of blood; Exclusion:; Early stage kidney cancer; Patients who do not have kidney cancer; Patients with RCC that do not intend to receive systemic therapy; Patients who have already commenced systemic therapy with no plans of changing the systemic therapy after the collection of the core needle biopsy; Any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding that, in the investigator's opinion, gives reasonable suspicion of a disease or condition that may affect the interpretation of the results, render the patient at high risk from treatment complications or interferes with obtaining informed consent; Previous diagnosis of other cancer. Previously treated cancer may be acceptable in some circumstances (e.g. surgery for an unrelated cancer > 5 years ago) after discussion with the Sponsor; No lesions are amenable to biopsy.